2.06 USD
+0.47 (+29.56%)
1.92 USD
-0.14 (-6.8%)
Overall CHRS gets a fundamental rating of 2 out of 10. We evaluated CHRS against 525 industry peers in the Biotechnology industry. Both the profitability and financial health of CHRS have multiple concerns. CHRS has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- In the past year CHRS has reported negative net income.
- In the past year CHRS has reported a negative cash flow from operations.
- In multiple years CHRS reported negative net income over the last 5 years.
- In the past 5 years CHRS reported 4 times negative operating cash flow.
1.2 Ratios
- CHRS's Return On Assets of 30.00% is amongst the best of the industry. CHRS outperforms 98.29% of its industry peers.
- CHRS's Return On Equity of 176.56% is amongst the best of the industry. CHRS outperforms 99.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30% | ||
| ROE | 176.56% | ||
| ROIC | N/A |
ROA(3y)-30.71%
ROA(5y)-23.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With an excellent Profit Margin value of 185.44%, CHRS belongs to the best of the industry, outperforming 98.86% of the companies in the same industry.
- CHRS's Profit Margin has declined in the last couple of years.
- CHRS has a better Gross Margin (47.79%) than 75.24% of its industry peers.
- CHRS's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 185.44% | ||
| GM | 47.79% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-15.79%
GM growth 3Y-12.08%
GM growth 5Y-10.08%
2. Health
2.1 Basic Checks
- CHRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
- CHRS has more shares outstanding than it did 1 year ago.
- CHRS has more shares outstanding than it did 5 years ago.
- CHRS has a better debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of -4.02, we must say that CHRS is in the distress zone and has some risk of bankruptcy.
- With a Altman-Z score value of -4.02, CHRS perfoms like the industry average, outperforming 42.86% of the companies in the same industry.
- A Debt/Equity ratio of 0.58 indicates that CHRS is somewhat dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.58, CHRS is doing worse than 70.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.58 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.02 |
ROIC/WACCN/A
WACC8.74%
2.3 Liquidity
- CHRS has a Current Ratio of 1.24. This is a normal value and indicates that CHRS is financially healthy and should not expect problems in meeting its short term obligations.
- CHRS has a Current ratio of 1.24. This is amonst the worse of the industry: CHRS underperforms 83.81% of its industry peers.
- CHRS has a Quick Ratio of 1.23. This is a normal value and indicates that CHRS is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 1.23, CHRS is doing worse than 83.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.24 | ||
| Quick Ratio | 1.23 |
3. Growth
3.1 Past
- The earnings per share for CHRS have decreased strongly by -19.27% in the last year.
- Measured over the past years, CHRS shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -27.39% on average per year.
- Looking at the last year, CHRS shows a very negative growth in Revenue. The Revenue has decreased by -72.54% in the last year.
- The Revenue has been decreasing by -5.60% on average over the past years.
EPS 1Y (TTM)-19.27%
EPS 3YN/A
EPS 5Y-27.39%
EPS Q2Q%-3200%
Revenue 1Y (TTM)-72.54%
Revenue growth 3Y-6.5%
Revenue growth 5Y-5.6%
Sales Q2Q%-83.65%
3.2 Future
- The Earnings Per Share is expected to decrease by -4.36% on average over the next years.
- CHRS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.39% yearly.
EPS Next Y-95.39%
EPS Next 2Y-14.02%
EPS Next 3Y-4.33%
EPS Next 5Y-4.36%
Revenue Next Year-83.13%
Revenue Next 2Y-44.95%
Revenue Next 3Y-26.95%
Revenue Next 5Y0.39%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for CHRS. In the last year negative earnings were reported.
- Also next year CHRS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- CHRS's earnings are expected to decrease with -4.33% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.02%
EPS Next 3Y-4.33%
5. Dividend
5.1 Amount
- CHRS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
COHERUS ONCOLOGY INC / CHRS FAQ
What is the ChartMill fundamental rating of COHERUS ONCOLOGY INC (CHRS) stock?
ChartMill assigns a fundamental rating of 2 / 10 to CHRS.
What is the valuation status of COHERUS ONCOLOGY INC (CHRS) stock?
ChartMill assigns a valuation rating of 0 / 10 to COHERUS ONCOLOGY INC (CHRS). This can be considered as Overvalued.
Can you provide the profitability details for COHERUS ONCOLOGY INC?
COHERUS ONCOLOGY INC (CHRS) has a profitability rating of 3 / 10.
What is the expected EPS growth for COHERUS ONCOLOGY INC (CHRS) stock?
The Earnings per Share (EPS) of COHERUS ONCOLOGY INC (CHRS) is expected to decline by -95.39% in the next year.